benzinga.com
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?
An interchangeable FDA approval can increase availability and potentially reduce costs for biologic treatments used in Crohn’s disease and ulcerative colitis. This may affect medication access, pharmacy substitution, and insurance coverage for patients on ustekinumab or similar biologics.
Patients with Crohn’s disease or ulcerative colitis on or considering ustekinumab; caregivers; clinicians, pharmacists, and health systems managing biologic therapies; researchers and industry watchers tracking biosimilars.
What To Know
The FDA approved Teva/Alvotech’s biosimilar Selarsdi (ustekinumab-aekn) as interchangeable with the reference biologic Stelara (ustekinumab) and it is available in multiple presentations for indications that include Crohn’s disease and ulcerative colitis.
The article also notes Teva’s prior interchangeable adalimumab biosimilar (Simlandi) and pending biosimilar BLAs (including an AVT05 golimumab candidate) under review. Coverage is primarily about approvals, commercialization, and Teva’s biosimilars strategy rather than clinical guidance.
Selarsdi is an FDA-approved interchangeable biosimilar to Stelara; interchangeable designation means pharmacists can substitute it for the reference product where allowed by law. The article lists the approved presentations and says Selarsdi is approved for indications that include Crohn’s disease and ulcerative colitis.
Teva and Alvotech’s partnership has produced multiple biosimilar approvals and additional candidates in review, which is the main reason the company’s stock moved. No clinical recommendations or comparative effectiveness data are provided in the article.
If you are on ustekinumab or another biologic, any switch to a biosimilar would be handled by your care team and pharmacy; this article reports a regulatory/market development rather than clinical trial outcomes.
People with Crohn’s disease or ulcerative colitis who are treated with ustekinumab, patients on biologic therapy concerned about cost or access, clinicians and pharmacists, and researchers or industry observers following biosimilar approvals. This is a regulatory and business-focused report about FDA interchangeability approval and commercial launches.
It does not present new clinical trial results or
Interchangeability and market launch are regulatory and commercial milestones; they do not automatically change individual treatment decisions. Coverage, pharmacy substitution policies, and clinical monitoring after any switch are determined by prescribers, payers, and pharmacies.
The article focuses on Teva’s business strategy and FDA approvals rather than clinical efficacy or safety comparisons.
